Skip to main content
SpringerLink
Log in

Meta-analysis of the second collaborative study of adjuvant chemoendocrine therapy for breast cancer (acetbc) in patients with stage ii, estrogen-receptor-positive breast cancer

  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

The second 5-year study of postoperative adjuvant therapy in patients with breast cancer between 1985 and 1988 was performed by the Study Group for Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC). This report describes the results of a meta-analysis of the outcome. A total of 3012 patients with stage II, estrogen-receptor-positive primary breast cancer who underwent radical surgery (total mastectomy with at least axillary dissection) were eligible for the analyses. On the day of surgery, all patients received 13 mg/m2 of mitomycin C (MMC) intravenously. Patients were then given one of two adjuvant chemoendocrine therapies for 2 years: regimen A, consisting of tamoxifen citrate (TAM) 30 mg/day, or regimen B, consisting of TAM 30 mg/day plus tegafur (Futraful, FT) 600 mg/day. The results from all eligible patients were included in a meta-analysis according to the method of Petoet al. The odds reduction rate was 12 ± 13% (log-rank test,p = 0.35) for the 5-year survival rate and 16±10% (log-rank test, p = 0.093) for the 5-year non-recurrence rate. In terms of the 5-year non-recurrence rate, regimen B (with FT) yielded slightly, but not significantly, better results than regimen A. In addition, stratified analyses were carried out with respect to the 5-year non-recurrence rate. Regimen B (with FT) yielded significantly better results than regimen A in patients with four or more positive axillary nodes (log-rank test,p = 0.039) and yielded slightly, but not significantly, better results than regimen A in premenopausal patients (log-rank test,p = 0.079).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ACETBC:

Adjuvant chemoendocrine therapy for breast cancer

ER:

Estrogen receptor

MMC:

Mitomycin C

TAM:

Tamoxifen citrate

FT:

Futraful

CMF:

Cyclophosphamide+methotrexate+fluorouracil

CPA:

Cyclophosphamide

EBCTCG:

Early Breast Cancer Trialisrs’ Collaborative Group

QOL:

Quality of life

References

  1. Rossi A, Bonadonna G, Valagussa P,et al: Multimodal treatment in operable breast cancer; Five- year results of the CMF programme.Br Med J 282: 1427–1431, 1981.

    CAS  Google Scholar 

  2. Yoshimoto M, Kasumi F, Watanabe S,et al: Ten- year follow-up mitomycin C single agent adjuvant chemotherapy for breast cancer. In: Taguchi T, Andrysek O eds, New Trends in Cancer Chemotherapy with Mitomycin C, Excerpta Medica, Tokyo, pp58–67, 1987.

    Google Scholar 

  3. Konda C, Niitani H, Sakauchi N,et al: Chemotherapy of cancer with oral administration of N1-(2-furanidil)- 5-fluorouracil [FT-207].Jpn J Cancer Clin 19:495- 499, 1973 (in Japanese with English summary).

    Google Scholar 

  4. Ansfield FJ, Kallas GJ, Singson JP: Phase III studies of oral tegafur (Futraful).J Clin Oncol 1:107–110, 1983.

    PubMed  CAS  Google Scholar 

  5. Adachi I: Clinical studies on the treatment of the patients with advanced breast cancer.Jpn J Cancer Chemother 21:72–78, 1981 (in Japanese with English summary).

    Google Scholar 

  6. Wada T, Koyama H, Nishizawa Y,et al: Chemoendocrine therapy for advanced breast cancer; A combined treatment with tamoxifen and FT-207.J Jpn Soc Cancer Ther 16:51–55, 1981 (in Japanese with English summary).

    CAS  Google Scholar 

  7. Abe O: The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer; Metaanalysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC).Breast Cancer 1:1–9, 1994.

    Article  Google Scholar 

  8. Goldhirsch A: Meeting highlights; International panel on the treatment of primary breast cancer.JNCI 87: 1441–1445, 1995.

    Article  PubMed  CAS  Google Scholar 

  9. Early Breast Cancer Trialists’ Collaborative Group: Treatment of Early Breast Cancer, Vol 1; Worldwide Evidence 1985–1990. Oxford University Press, Oxford, pp12–19, 1990.

    Google Scholar 

  10. Sakamoto G: Characteristics and future prospect of breast cancer in Japan.Jpn J Breast Cancer 2:327–338, 1987 (in Japanese with English summary).

    Google Scholar 

  11. Baum M: Prospects for the future in the management of carcinoma of the breast; The biological fall out from clinical trials. In: Jones SE, Salmon SE eds, Adjuvant Therapy of Cancer IV, Groune & Stratton Inc, Orlando, pp321–329, 1984.

    Google Scholar 

  12. Tormy DC, Taylor SG, Kalish LA,et al: Adjuvant systemic therapy in premenopausal (CMF, CMFP, CMFPT) and postmenopausal (observation, CMFP, CMFPT) women with node positive breast cancer. In: Jones SE, Salmon SE eds, Adjuvant Therapy of Cancer IV, Groune & Stratton Inc, Orlando, pp359- 368, 1984.

    Google Scholar 

  13. Fisher B: Treatment of primary breast cancer with L- PAM/5-FU and tamoxifen; An interim report.Breast Cancer Res Treat 3(Suppl 1):7–17, 1983.

    Article  Google Scholar 

  14. Palshof T, Carstensen B, Mouridsen HT,et al. Reviews on Endocrine-Related Cancer 17(Suppl):43- 50, 1985.

    Google Scholar 

  15. Wallgren A, Baral E, Carstensen J,et al: Should adjuvant tamoxifen be given for several years in breast cancer? In: Jones SE, Salmon SE eds, Adjuvant Therapy of Cancer IV, Groune & Stratton Inc, Orlando, pp331–337, 1984.

    Google Scholar 

  16. Patterson JS, Battersby LA, Edwards DG: Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. In: Lacobelli S, {eaet al} eds, The Role of Tamoxifen in Breast Cancer, Raven Press, ppl7–29, 1982.

  17. Margreiter R, Wiegele J: Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer.Breast Cancer Res Treat 4:45–48, 1984.

    Article  PubMed  CAS  Google Scholar 

  18. Tancini G, Bonadonna G, Valagussa P,et al: Adjuvant CMF in breast cancer; Comparative 5-year results of 12 versus 6 cycles.J Clin Oncol 1:2–10, 1983.

    PubMed  CAS  Google Scholar 

  19. Smalley RV, Bartolucci AA, Moore M,et al: Southeastern Cancer Study Group: Breast cancer studies 1972–1982.Int J Radiat Oncol Biol Phys 9:1867–1874, 1983.

    PubMed  CAS  Google Scholar 

  20. Brincker H, Mouridsen HT, Andersen KW: Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal woman with stage II breast cancer.Breast Cancer Res Treat 3:91–95, 1983.

    Article  PubMed  CAS  Google Scholar 

  21. Howell A, Bush H, George WD,et al: Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.Lancet 2:307–311, 1984.

    Article  PubMed  CAS  Google Scholar 

  22. Nissen-Meyer R, Host H, Kjellgren K,et al: Scandinavian trials with short postoperative course versus a 12-cycle course.Recent Results Cancer Res 96:48- 54, 1984.

    PubMed  CAS  Google Scholar 

  23. Tormy DC, Weinberg VE, Holland JF,et al: A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.J Clin Oncol 1:138–145, 1983.

    Google Scholar 

  24. Izuo M: Clinicopathological features of recurrent breast cancer.Jpn J Cancer Chem 12(Part I):412–420, 1985 (in Japanese with English summary).

    CAS  Google Scholar 

  25. Buyse M: Potential and pitfalls of randomized clinical trials in cancer research.Cancer Surv 8:91–105, 1989.

    PubMed  CAS  Google Scholar 

  26. Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy.Lancet 339:1–15, 71-85, 1992.

    Google Scholar 

  27. Nomura Y, Tominaga T, Adachi I,et al: Clinical evaluation of cyclophosphamide, methotrexate and 5- fluorouracil (CMF) on advanced and recurrent breast cancer.Jpn J Cancer Chemother 21:1949–1956, 1994 (in Japanese with English summary).

    CAS  Google Scholar 

  28. Tormy C: Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma; The GALGB trial and ECOG premenopausal trial.Recent Results Cancer Res 96:153–165, 1984.

    Google Scholar 

  29. Yasumura T, Oka T, Honjo H: Menstrual abnormality in breast cancer patients receiving adjuvant endocrino-chemotherapy.Jpn J Cancer Chemother 15:2947- 2952, 1988 (in Japanese with English summary).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aichi Cancer Center Hospital, Chief Investigator of the Chubu Region, 1-1, Kanokoden, Chikusa-ku, 464, Nagoya, Japan

    Minoru Yoshida

  2. St. Luke’s International Hospital, Chairman of ACETBC and Chief Investigator of the Kanto Region, Japan

    Osahiko Abe

  3. The First Department of Surgery, Hokkaido University School of Medicine, Chief Investigator of the Hokkaido Region, Japan

    Junichi Uchino

  4. National Sendai Hospital, Chief Investigator of the Tohoku Region, Japan

    Kaneo Kikuchi

  5. The Second Department of Surgery, Fukushima Medical College, Administrator of the Tohoku Region, Japan

    Rikiya Abe

  6. Department of Surgery, School of Medicine, Keio University, Deputy Investigator of Organizing and Steering Committee of the Kanto Region, Japan

    Kohji Enomoto

  7. Tokyo Metropolitan Komagome Hospital, Chairman of Organizing and Steering Committee of the Kanto Region, Japan

    Takeshi Tominaga

  8. Kameda General Hospital, Investigator of Organizing Committee and Steering Committee of the Kanto Region, Japan

    Atsuo Fukami

  9. The Second Department of Surgery, Faculty of Medicine, Kyushu University, Co-chief Investigator of the Nishinihon Region, Japan

    Keizo Sugimachi

  10. Department of Breast Surgery, National Kyushu Cancer Center Hospital, Co-chief Investigator of the Nishinihon Region, Japan

    Yasuo Nomura

  11. Hiroshima University, Former Chief Investigator of the Nishinihon Region, Japan

    Takao Hattori

  12. Ehime University, Controller, Japan

    Nobuya Ogawa

Authors
  1. Minoru Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osahiko Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junichi Uchino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kaneo Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rikiya Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kohji Enomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takeshi Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsuo Fukami
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Keizo Sugimachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuo Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takao Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Nobuya Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Yoshida, M., Abe, O., Uchino, J. et al. Meta-analysis of the second collaborative study of adjuvant chemoendocrine therapy for breast cancer (acetbc) in patients with stage ii, estrogen-receptor-positive breast cancer. Breast Cancer 4, 93–101 (1997). https://doi.org/10.1007/BF02967062

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967062

Key words

Search

Navigation